dn-101
End Stage Renal Disease
National Center for Research Resources (NCRR)Small moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the End Stage Renal Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOXETINE University of Arkansas | Phase 4 | BB |
Sertraline University of Washington | Phase 3 | BB |
Buprenorphine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | B |
Genotropin National Center for Research Resources (NCRR) | Phase 2 | B |
Cyclophosphamide Massachusetts General Hospital | Phase 1 | CC |
View all 10 →
Same molecule, other indications
dn-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →